Company Filing History:
Years Active: 2016
Title: Shuangyi Wan: Innovator in Antidiabetic Compounds
Introduction
Shuangyi Wan is a notable inventor based in Pittsburgh, PA, who has made significant contributions to the field of pharmaceuticals. His work primarily focuses on developing innovative compounds aimed at regulating insulin levels in mammals, particularly in relation to Type 2 diabetes mellitus.
Latest Patents
Shuangyi Wan holds a patent for "Bridged and fused antidiabetic compounds." This invention provides for certain bridged and fused compounds that act as agonists of the G-protein coupled receptor 40 (GPR40), also known as the free fatty acid receptor FFAR. The patent outlines the formula for these compounds and their potential applications in pharmaceutical compositions. These compounds are designed to help regulate insulin levels and may be used in the prevention and treatment of Type 2 diabetes mellitus, as well as related conditions such as insulin resistance, obesity, and lipid disorders.
Career Highlights
Shuangyi Wan is currently employed at Merck Sharp & Dohme Corporation, a leading global healthcare company. His work at Merck has allowed him to focus on innovative solutions in the pharmaceutical industry, contributing to advancements in diabetes treatment.
Collaborations
Some of Shuangyi Wan's notable coworkers include Hubert B Josien and John W Clader. Their collaborative efforts in research and development have further enhanced the impact of their work in the field of antidiabetic compounds.
Conclusion
Shuangyi Wan's contributions to the development of antidiabetic compounds highlight his role as an innovator in the pharmaceutical industry. His patent for bridged and fused compounds represents a significant advancement in the treatment of Type 2 diabetes mellitus and related conditions.